Neuroinflammation in COVID-19 and Depression

NCT ID: NCT04854785

Last Updated: 2025-04-22

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 77 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-06-14
• Study Completion Date: 2023-12-21

Brief Summary

The purpose of this study is to use state of the art brain imaging technology to investigate neuroinflammation in participants with depression after the respiratory symptoms of coronavirus disease 2019 (COVID-19) have passed.

Detailed Description

Participants will undergo two positron emission tomography (PET) scans: one [18F]FEPPA scan (for translocator protein (TSPO)) and one [11C]SL25.1188 scan (for monoamine oxidase B (MAO-B)) - as well as one magnetic resonance imaging (MRI) scan.

The primary hypotheses are:

1. TSPO total distribution volume (TSPO VT) and MAO-B total distribution volume (MAO-B VT) are greater in the prefrontal cortex (PFC), anterior cingulate cortex (ACC), and hippocampus in COVID-19 with new onset, persistent major depressive episode (MDE) with or without other neuropsychiatric symptoms after recovery from mild respiratory symptoms (DNP-mild).

2. TSPO VT and MAO-B VT are greater in the PFC, ACC, and hippocampus in COVID-19 with new onset, persistent MDE with or without other persistent neuropsychiatric symptoms after recovery from moderate respiratory symptoms (DNP-moderate).

Exploratory hypotheses are:

1. Greater TSPO VT and MAO-B VT in the PFC, ACC, and hippocampus will be positively associated with severity of MDE symptoms and poorer performance on cognitive tasks.

2. TSPO VT and MAO-B VT will be positively correlated in the PFC, ACC and hippocampus in COVID-DNP.

Conditions

Major Depressive Episode; Covid19

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Study Groups

DNP-mild

Participants that have recovered from mild COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).

[18F]FEPPA PET scan

Intervention Type: OTHER

One \[18F\]FEPPA PET for TSPO VT, and one MRI scan

[11C]SL25.1188 PET scan

Intervention Type: OTHER

One \[11C\]SL25.1188 PET scan for MAO-B VT, and one MRI scan

DNP-moderate

Participants that have recovered from moderate COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).

[18F]FEPPA PET scan

Intervention Type: OTHER

One \[18F\]FEPPA PET for TSPO VT, and one MRI scan

[11C]SL25.1188 PET scan

Intervention Type: OTHER

One \[11C\]SL25.1188 PET scan for MAO-B VT, and one MRI scan

Healthy Control Participants

Participants in good physical health, age- and sex-matched to Group 1 and 2 participants.

[18F]FEPPA PET scan

Intervention Type: OTHER

One \[18F\]FEPPA PET for TSPO VT, and one MRI scan

[11C]SL25.1188 PET scan

Intervention Type: OTHER

One \[11C\]SL25.1188 PET scan for MAO-B VT, and one MRI scan

Interventions

[18F]FEPPA PET scan

One \[18F\]FEPPA PET for TSPO VT, and one MRI scan

Intervention Type: OTHER

[11C]SL25.1188 PET scan

One \[11C\]SL25.1188 PET scan for MAO-B VT, and one MRI scan

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Age 18 to 80
• Diagnosis of COVID-19
• Recovered from mild or moderate COVID-19 symptoms. Mild is defined as no evidence of pneumonia or hypoxia. Moderate is defined as presence of clinical symptoms of pneumonia but not severe enough to require ongoing use of supplementary oxygen.
• Recovered from physical COVID-19 symptoms including cough, shortness of breath, fever, chills, or gastrointestinal upset for at least 4 weeks
• New onset major depressive episode (MDE) within 3 months after COVID-19, as verified by the Research Version of Structured Clinical Interview for DSM 5 (SCID-5-RV)
• High-affinity-binder (HAB) or mixed-affinity-binder (MAB) genotype for rs6971 polymorphism, based on saliva genetic testing

Exclusion Criteria

• Lifetime history of an autoimmune disease
• Lifetime history of a neurological disease, excluding migraine
• Lifetime diagnosis of Antisocial or Borderline Personality disorder
• Lifetime history of psychotic symptoms prior to COVID-19
• Lifetime diagnosis of Substance of Alcohol Use Disorder
• Use of street drugs, including marijuana, in the past two months
• Presence of cigarette smoking in the past two months
• Positive urine drug or cotinine screen at any timepoint during the study
• Currently pregnant
• Currently breastfeeding
• Use of aspirin or ibuprofen within the past 2 weeks
• Use of any other anti-inflammatory medication or MAO-B inhibitors within the past 4 weeks
• Use of herbal remedies in the past month
• Presence of metal implant, object or electrical devices that are contraindicated for MRI
• Current disorders of coagulation, blood or ongoing use of anticoagulant medication
• Claustrophobia
• Weight over 400lbs and height over 7ft
• History of undergoing a number of PET scans that will lead participants to exceed the annual (20mSv) / lifetime (8 PET scans) radiation by completing this study
• Current participation in another research study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Centre for Addiction and Mental Health

OTHER

Sponsor Role: lead

Responsible Party

Jeff Meyer

Program Head, Neurochemical Imaging for Mood Disorders

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jeffrey H Meyer, M.D., PhD

Role: PRINCIPAL_INVESTIGATOR

Brain Health Imaging Centre, Centre for Addiction and Mental Health (CAMH)

Locations

Centre for Addiction and Mental Health

Toronto, Ontario, Canada

Countries

Canada

Other Identifiers

177/2020

Identifier Type: -

Identifier Source: org_study_id